Lorem Ipsum
Chief Executive Officer

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Sigal Atzmon
CEO, Medix Group

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Maija Burtmanis
Campbell Clark, VP, Legal and Compliance, Medtronic

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Alan Dy
Global Head SCM, Novartis

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Dr. Ferdinal Fernando
MD, MDM, Assistant Director & Head of Health Division (HD), ASEAN Secretariat

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Khairy Jamaluddin
Minister of Health, MoH MY

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Chris Cave Jones
Regional Director, Argon & Co

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Dr. Lee Po-Chang
Director General, NHIA Taiwan

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Loke Wai Chiong
Clinical Director and Program Lead, MOHT

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

John Graham
Chief Executive Officer, Zuellig Pharma

John Graham leads the Zuellig Pharma Executive Management team and runs the US$13 billion business across 13 markets in Asia. His vision is to lead the transformation of the business, define its mission to make healthcare more accessible through world-class distribution, digital technology, and commercial solutions.

John brings with him over 30 years of experience in biotech, pharmaceuticals and healthcare consulting. He has previously held various leadership positions including the role of CEO Invida, where he successfully positioned the business as a leading commercialization specialist in the region. Invida was acquired by A. Menarini where John continued as CEO of Menarini Asia Pacific until 2015, transforming the business into a regional pharma company.

John started his career with Aventis, where he spent 18 years in various operational and global leadership positions including regional responsibilities in Latin America, Head of Global Diabetes, and Global VP of New Products. Following that, he was Managing Director of Genzyme's operations in Germany and Switzerland before building up a Life Sciences Advisory Practice at Ernst & Young.

Robert Kruit
Senior VP Client Development & South East Asia, Zuellig Pharma

Robert is responsible for the development of strategic relationships with Zuellig Pharma’s regional clients, in addition to the South East Asia markets. He joined Zuellig Pharma in 2011, and has held country leadership roles in Bangladesh, Vietnam and Malaysia. Prior to Zuellig Pharma, he has worked with Heineken and Hilton in Europe and the Middle East. Robert holds an MBA and MSc from Heriot-Watt and an Executive Master in Change from INSEAD.

Brett Marshall
VP Quality Assurance, Zuellig Pharma

Brett Marshall is the Vice President of Quality Assurance at Zuellig Pharma, one of the largest healthcare services groups in Asia with a mission of making healthcare more accessible. Based in Singapore, Brett has direct reporting lines from quality assurance heads in 13 Countries and quality oversight of clinical reach operations in another 4 Countries.

Brett is a strong advocate of change for the quality landscape in Asia. He actively drives more effective risk management in the cold chain, supplier management and digitisation opportunities driving to Industry 4.0 in the quality space.

Originally from Melbourne, Australia, Brett has a bachelor's degree in transport and logistics management from RMIT. He has 25 years’ experience in executive management, logistics and supply chain, business process transformation and quality assurance and 15 years in the pharma industry. He has spent more than 20 years living in Asia including Indonesia, Thailand, the Philippines, Bangladesh and now Singapore.

Chris Humphrey
Executive Director, EU-ASEAN Business Council

Chris Humphrey is a Business Development and Government Relations professional with more than a decade of experience running business units throughout Asia, and over 20 years of experience of either working for or dealing with Governments and regulatory authorities.

Chris began his varied professional career as a UK Civil Servant where, amongst other things, he was a Private Secretary to a Minister and an Air Services Trade Negotiator covering the Asia Pacific Region.

After leaving Government, Chris moved to the private sector working initially in the Government and external relations teams at two British airlines, before moving to Shanghai, China with Virgin Atlantic where he headed up the airline’s China operation and oversaw the rapid expansion of their business in China. Whilst in Shanghai, Chris also sat on the Executive Committee of the British Chamber of Commerce. After a short spell in Hong Kong with Virgin, Chris then joined a UK based security and defence group where he led their Asia Pacific team for over five years and was instrumental in them getting contracts with the Japanese and Singapore Governments and also with SOEs in China.

More recently Chris has been acting as a consultant assisting start-ups in Asia with their business and corporate development before joining the EU-ASEAN Business Council in June 2014.

Rehan Q. Saghir
Executive Vice President, ZP Therapeutics

Rehan leads Zuellig Pharma’s ZP Therapeutics business, where he oversees a passionate team of 2500 associates contributing to making healthcare more accessible through the development of sales, marketing, medical, access, commercial excellence, business development, HR, finance, compliance and regulatory strategies. He leads the team to support both established and newly launched ethical and consumer healthcare brands and drives the adoption of innovative digital tools for business growth.

Rehan brings with him over 30 years of experience in various industries and leadership roles including sales and marketing, manufacturing, finance, medical and human resources. He joins Zuellig Pharma from Eli Lilly where he was General Manager for ASEAN and Thailand overseeing the company’s operations in Southeast Asia. He first joined Eli Lilly in 1994 as finance manager and was promoted to various senior executive roles including GM Pakistan & Bangladesh, Area Director Southeast Asia, GM ASEAN and Senior Human Resources Director for Asia Operations where he supported employees across Korea, Taiwan, India, Hong Kong, Pakistan, Bangladesh and ASEAN.

He started his career at KPMG Peat Marwick (United Kingdom) and is a strong believer in growing people and businesses underpinned by the five Ps –People, Products, Process, Performance and Passion. Rehan is a qualified Chartered Accountant from England & Wales. He holds a Bachelor of Commerce from the University of Karachi in Pakistan and is currently based in Zuellig Pharma’s Regional Office in Singapore.

Daniel Laverick
Vice-President, Head of Digital & Data Solutions, Zuellig Pharma

Daniel Laverick is the Head of Digital & Data Solutions at Zuellig Pharma. An advocate for the use of technology to drive digital transformation and innovation, Daniel has more than 20 years’ experience working in MNCs across Pharma, Banking, Oil & Gas and Telecoms.

In his role as Head of Digital & Data solutions, Daniel is responsible for strategising and leading teams to develop new solutions using the latest platforms including the Internet of Things (IoT), Machine Learning, Blockchain and others. An SAP and IT solutions expert, he previously managed and oversaw the largest SAP migration in Asia to public cloud, along with the development of eZTracker, Asia’s first blockchain-powered end-to-end traceability solution for supply chain connectivity at Zuellig Pharma.

In addition to overseeing strategy and implementation of the Data & Digital solutions portfolio including Data Analytics, eZRx – a B2B healthcare eCommerce platform, and eZTracker, Daniel also actively champions the mission of making healthcare more accessible and believes in empowering the Digital & Data teams to learn more, fail fast, and do good.

Jeff Weisel
Managing Director, APAC, PRMA Consulting Ltd

Jeff Weisel has more than 25 years’ experience working with leading life sciences and healthcare organizations on issues of strategic and business innovation, transactions and access to healthcare with focus on Asia-Pacific. He has advised corporate players, industry start-ups and institutional investors. He is currently regional Managing Director for PRMA Consulting, a technology-enabled consultancy accelerating market access globally for biopharma and medtech clients. Jeff has lived in Asia since 1994 and is based in Singapore.

Prior to PRMA, Jeff led strategy and transactions advisory work for life sciences and healthcare clients with EY. Before that he ran a boutique advisory firm focused on capitalization and commercialization of healthtech, medtech and biotech start-ups from Southeast Asia, Australia and the US.

Previously, Jeff was Market Access & Policy Director for Asia, Australia, Africa, Middle East for Abbott (now AbbVie) where he developed and led the company’s engagement with governments, payers and other stakeholders. Before Abbott, he launched new businesses in patient and payer solutions for Zuellig Pharma, the largest provider of services to the healthcare industry in Asia. Earlier, Jeff led Novartis in major growth initiatives across Asia–Pacific in business development and licensing (more than 40 transactions), market access and strategic planning. In these leadership roles, he helped deliver the regional success of top global brands such as Humira, Lucentis and Diovan.

Jeff has served on the Board of Governors and as chair of the Healthcare Committee for the American Chamber of Commerce in Singapore. He has also been a lecturer on market access strategy at the ESSEC Business School, a member of the Singapore National Health Innovation Center’s expert panel on new medical technologies and a strategy/commercial mentor for start-ups under the Graduate Research Innovation Program (GRIP) at the National University of Singapore.

He holds an M.A in Asian Studies and Economics from George Washington University and a B.A. in Political Science from Boston University.